| | | |  | | | | | | | | | | | | | | | |  | | | | :: | | | :: | | | :: | | | :: | | | :: | | | :: | | | :: | | | :: | | | :: | | | :: | | | | | | | | | | | | | | | | | RNAi Therapeutics Sponsored Links - Acuity Pharmaceuticals
 - Acuity Pharmaceuticals is a product-focused ophthalmic pharmaceutical company leveraging its strong technology portfolio in RNA interference. Acuity is focusing on developing treatments for age-related macular degeneration (AMD) and diabetic retinopathy (DR), two of the leading causes of vision loss in the developed world.
- Alnylam Pharmaceuticals - Alnylam Pharmaceuticals (ALNY, NASDAQ), a leader in RNAi therapeutics, is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi; a discovery that enables the creation of a broad new class of human therapeutics. Using RNAi, Alnylam has built a product engine to develop a deep pipeline of drug products to treat a wide array of important diseases.
- Atugen AG - Atugen AG, the RNAi Therapeutics Company, is a biopharmaceutical company based in Berlin, Germany currently employing about 40 individuals. Atugen's therapeutic siRNA programs focus on in vivo applications in oncology and liver diseases, exploiting its proprietary oligonucleotide delivery technologies and chemically stabilized siRNA structures (atuRNAi).
- Benitec - Benitec, a leading international biotechnology company listed on the Australian Stock Exchange, develops RNA interference (RNAi)-based therapeutics to treat serious diseases such as AIDS and hepatitis C.
- Calando Pharmaceuticals - Calando Pharmaceuticals is focused on designing, developing and commercializing new RNAi therapeutics to treat and cure diseases and other medical conditions by combining effective RNAi therapeutics with our patented and proprietary delivery technologies.
- CytRx - CytRx Corporation (NASDAQ: CYTR), located in Los Angeles, California, is a biopharmaceutical company engaged in the development of high-value therapeutics utilizing its core technologies in small molecule drugs, RNAi drug discovery and DNA vaccines.
- Sirna Therapeutics - Sirna Therapeutics (RNAI, NASDAQ) initiated its first clinical trial of a chemically modified short interfering RNA (siRNA) for the treatment of Age-related Macular Degeneration (AMD) in November 2004.
|
